Urethritis

Summary

Urethritis (MONDO:0005297) is a disease with 1 GWAS associations across 8 studies and 7 clinical trials. Top therapeutic interventions include doxycycline anhydrous, azithromycin, and lymecycline. A subtype of urethral disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 1
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	urethritis
Mondo ID	MONDO:0005297
EFO	EFO:0003878
MeSH	D014526
DOID	DOID:1343
NCIT	C26904
SNOMED CT	84619001
UMLS	C0041976
MedGen	52934
Is cancer (heuristic)	no

Also known as: inflammation of urethra · Nongonococcal urethritis · urethra inflammation · urethritis · urethritis (disease)

Data availability: 1 GWAS association (8 studies) · 1 HPO phenotype.

Disease family

This is a subtype of urethral disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urethral disorder › urethritis

Related subtypes (9): prolapse of urethra, urethral obstruction, urethral intrinsic sphincter deficiency, urethral syndrome, urethral false passage, urethral calculus, urethral gland abscess, fibroepithelial polyp of urethra, urethra neoplasm

Subtypes (2): Ureaplasma urethritis, gonococcal urethritis

Genetics & variants

GWAS landscape

1 GWAS associations across 8 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs148092403	2e-06	RNU6-931P - RN7SKP199	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478551	Verma A	2024	5,889	432,625	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436430	Zhou W	2018	3,088	379,936	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90478550	Verma A	2024	2,417	114,001	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480900	Verma A	2024	2,417	114,001	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90652239	Liu TY	2025	803	192,000	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478549	Verma A	2024	735	57,257	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90482235	Verma A	2024	298	120,583	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90727130	Kim HI	2026	137	43,889	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs148092403	4	45515470	C>T		intergenic_variant	RNU6-931P - RN7SKP199	2e-06	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Azithromycin	Approved (phase 4)
Lidocaine	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Tinidazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01661985	PHASE4	UNKNOWN	Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced
NCT00358462	PHASE3	COMPLETED	Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)
NCT00207467	PHASE2	COMPLETED	Study to Improve Partner Services for STD Prevention
NCT00322465	PHASE2	COMPLETED	NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
NCT01732172	Not specified	COMPLETED	Chronic Inflammatory Condition of the Male Genital Tract
NCT05564299	Not specified	COMPLETED	Rapid Diagnostic Assay for Gonorrhea and Chlamydia
NCT06951009	Not specified	COMPLETED	Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXYCYCLINE ANHYDROUS	4	7
AZITHROMYCIN	4	1
LYMECYCLINE	4	1
TINIDAZOLE	4	1
CHEMBL4299381	0	1
CHEMBL4303727	0	1